Epidermal Growth Factor receptor (EGFR) expression is high in pancreatic cancer.
Introduction
In the Western world, approximately 5% of cancer mortality is due to pancreatic ductal adenocarcinoma (PDAC). At presentation, only 10-20% of patients with PDAC have localized disease that can be considered for resection. The remaining patients cannot be cured with resection due to locally advanced pancreatic cancer (LAPC) (approximately 35%) or metastatic disease.
Treatment of LAPC is extremely challenging. Despite recent advances in the treatment of metastatic pancreatic cancer using combination chemotherapy regimens including oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX)(1) or gemcitabine-paclitaxel protein-bound (2) , not much progress has been made in the treatment of LAPC in the last decade. Since both metastatic spread and locoregional disease progression are of major concern, combinations of systemic chemotherapy and radiotherapy are often used. Numerous chemoradiotherapy (CRT) studies have been performed, attempting to postpone disease progression and also to increase the possibility of resection (3, 4) . Results of these CRT regimens are comparable, and do not consistently show benefit of combination treatment or from chemotherapy alone (5) . However, a recent meta-analysis including 15 randomized trials in which CRT with radiotherapy (RT) or chemotherapy (CHT) alone were compared for LAPC, showed superiority of CRT in 6-and 12-months survival at the expense of more toxicity (6) . Survival at 18-months was not significantly different. Ongoing developments include the use of CRT regimens based upon full dose chemotherapy with added radiation, rather than the other way round (7, 8) or to add additional drugs to improve outcome of CRT (9) . Although CRT is considered as standard treatment for LAPC, improvement in efficacy and reduction of toxicity is urgently needed. Van Zweeden et al.
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The Epidermal Growth Factor Receptor (EGFR; also known as ErbB-1 and HER1 in humans) signaling cascade plays an important role in the biology of various malignancies, including pancreatic cancer. Human pancreatic cancer cells overexpress EGFR and its known ligands (10, 11) , which is correlated with rapidly progressive disease (12) . EGFR inhibition by the addition of erlotinib, a tyrosine kinase inhibitor, to gemcitabine is associated with a modest survival benefit in PDAC (13) . In colorectal cancer, the clinical efficacy of antibodies against EGFR is restricted to patients with wild-type RAS tumors (14, 15) . PDAC is known for its high K-RAS mutation phenotype (>90%) (16) and harbors the highest reported incidence of RAS mutations among all human cancers. These mutations rarely affect H-RAS or N-RAS and concentrate almost exclusively on the K-RAS locus, with reports of mutation rates up to 95% (17) .
Interestingly, several studies have shown that EGFR pathway inhibition can improve the antitumor efficacy of radiotherapy independent of the K-RAS mutation status of a tumor (18, 19) . Furthermore, preclinical in vivo studies indicated that the radiosensitizing activity of gemcitabine may be enhanced by specific EGFR inhibition (20) and also showed, in a pancreatic tumor model, that treatment with panitumumab, a fully human anti-EGFR monoclonal antibody (mAb), enhanced the antitumor efficacy of gemcitabine monotherapy (61% vs. 38% growth inhibition) (21) .
Panitumumab is generally well tolerated. Skin toxicity, hypomagnesaemia, and diarrhea are the most common toxicities observed (22) . Based on these promising preclinical data in favor of combining EGFR pathway inhibition (independent of K-RAS mutational status) with both gemcitabine and radiation therapy and the nonoverlapping toxicity profiles of gemcitabine and panitumumab, we designed a phase 
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I/II feasibility trial evaluating the addition of panitumumab to gemcitabine-based CRT in patients with locally advanced pancreatic cancer. Here we report the phase I feasibility part of this study. The primary endpoint was to determine the maximum tolerated dose (MTD) of panitumumab to be used in combination with gemcitabinebased CRT in patients with LAPC. Secondary end-points included early signs of clinical activity of the study treatment, clinical response rate, progression free survival (PFS) and overall survival (OS).
Patients and methods

Eligibility
Adult patients with untreated LAPC were eligible for this phase I trial. Encasement 
Study treatment
The treatment scheme is summarized in Figure 1 . The study was designed as 3+3 dose escalation clinical trial(23,24). Panitumumab was administered weekly for 6 weeks by iv infusion in different dose levels per cohort (1mg/kg, 1.5mg/kg, 2mg/kg and 2.5mg/kg) during gemcitabine-based CRT. Gemcitabine was administered weekly by iv infusion at a dose of 300mg/m2 during radiotherapy in the first six weeks, followed by a dose of 1000mg/m2 weekly for 3 weeks every 4 weeks from day 50 until disease progression or unacceptable toxicity and otherwise continued for a maximum period of one year. The radiotherapy schedule consisted of a dose of Clinical Cancer Research CCR-14-3364R, Manuscript resubmission 10 toxicities was allowed. All patients underwent a baseline CT scan and an efficacy evaluation CT after chemoradiation, during gemcitabine monotherapy at 3, 5, 7 and 9 months and every 3 months thereafter until progressive disease. The response evaluation criteria in solid tumors (RECIST) version 1.1 (26) were used for response assessment. Time to progression (TTP), mentioned in the study protocol as secondary endpoint, was defined as the time from registration in the study to progression or death whichever came first. TTP is further described in this study as PFS. Measurements of CA19.9 (U/ml) were performed before and during treatment.
CA19.9 response was defined as a decrease in CA19.9 concentration of at least 50% from the baseline concentration to the lowest value (nadir) measured during the study. 
Results
Patient characteristics
Twenty patients were registered in this study. Five patients were considered ineligible, because of either metastatic disease (n=3), elevated liver enzymes (n=1) and patient withdrawal before start of treatment (n=1). Between July 2010 and November 2013 treatment was initiated in 15 patients. One patient in the 1.5mg/kg cohort withdrew her consent after 2 weeks and was therefore considered not evaluable. The clinicopathologic characteristics of the 14 treated patients are listed in Table 1 .
DLT and maximum-tolerated and safe dose
No DLTs were observed in the first three patients in the first and second dose level (1mg/kg and 1.5mg/kg panitumumab). Two of the five patients treated in the third dose level (2mg/kg panitumumab) experienced a DLT and therefore this dose level was considered non-tolerable. One of these patients fulfilled the DLT criteria, because of nausea grade 3 despite optimal medical support including hospitalization.
This was reported as a serious adverse event (SAE) related to panitumumab in combination with gemcitabine and radiotherapy. The other patient experienced a DLT based on failure to complete the first 6 weeks of treatment as defined by the protocol, due to multiple grade 1-2 toxicities. The next 3 patients were enrolled in the second dose level (1.5mg/kg) and none had a DLT, providing the MTD as defined in the protocol. Toxicity was manageable at a panitumumab dose of 1.5 mg/kg (MTD). All 6
Research. Table 2 .
Rash, nausea, vomiting, weight loss, taste alteration, diarrhea, paronychia and dermatitis are considered as (possible) panitumumab related AEs. Four patients experienced hypomagnesaemia grade 1, three patients only during CRT, one patient also during the first 2 months of gemcitabine monotherapy. A total of 12 SAEs were reported in 8 of the 14 study participants which were evaluable for toxicity. Only one SAE was related to the study treatment. AEs reported after the CRT period (first 43 days) of the study are listed in supplement Table 1 . No unexpected AEs were reported during gemcitabine monotherapy.
Response, progression free survival an overall survival
One patient in the 1mg/kg cohort was diagnosed with LAPC based on cytology, but when he developed metastatic disease, histology revealed a pancreatic neuroendocrine tumor. Therefore this patient was evaluated for toxicity, but not for tumor response, PFS and OS. In Table 3 , the median PFS and OS of the patients treated in this study are shown. The median PFS of all cohorts together is 8.9 months (range 3.5-23), including one patient who had stable disease under study treatment 
Discussion
Here, we report the results of a phase I study designed to determine the safety, tolerability, and potential clinical efficacy of the anti-EGFR mAb panitumumab added to standard gemcitabine-based CRT in patients with LAPC. The MTD of panitumumab was determined to be 1.5mg/kg. We concluded that adding panitumumab to gemcitabine-based CRT is feasible with considerable, but manageable toxicity, as expected based on the non-overlapping toxicity profile of CRT and panitumumab. No differences in performance status, nodal status (Table 1) , comorbidity, intensity of radiotherapy (tumor-size and radiation fields were equal between the cohorts, supplement Table 2 ), or dosing of gemcitabine by itself could explain the observed DLTs in cohort three compared to the other two cohorts and were therefore most likely caused by the addition of a higher dose of panitumumab to the combination treatment. Major toxicities potentially related to the addition of panitumumab were nausea, vomiting, neutropenia, fatigue and anorexia, while acneiform rash was considered to be definitively related. These toxicities, apart from skin toxicity (22) , are not common for treatment with anti-EGFR mAb treatment, and are likely to be predominately caused by the combination with gemcitabine-based CRT (8, 27) . In addition, patients with LAPC often suffer from fatigue and gastrointestinal symptoms such as nausea and vomiting even without treatment. Because of these common gastrointestinal problems and the small number of patients per cohort in this study, we cannot rule out that establishing the MTD might be influenced by mild differences of gastrointestinal or even other complaints in the three cohorts before start of treatment. However, these differences were not clinically recognized despite intensive observation and there is no evidence of objective measurable months for the combination of gemcitabine 300mg/m2 weekly with radiotherapy (24Gy in 3 consecutive weekly fractions of 8Gy) (27) and for the combination of UFT 300mg/m2 daily, leucovorin 30mg and celecoxib 800mg daily for 28 days concomitant with radiotherapy (20×2.5Gy) (28) . In the present trial, radiation and chemotherapy seemed to be better tolerated compared to our previous studies. The day to day position variation (29) of pancreatic tumors and their intrafraction motion(30) due to breathing pose are challenging concerns in radiotherapy of LAPC.
Currently we tackle these issues by performing Image Guided Radiation Therapy (IGRT), using gold fiducial markers (31) . 
Our study is the first clinical trial in which panitumumab is combined with gemcitabine-based CRT in LAPC. Previously, the combination of panitumumab 6mg/kg on days 1, 15, and 29 in combination with 5FU/capecitabine-based CRT followed by gemcitabine and panitumumab followed by maintenance panitumumab for 6 months in LAPC was reported at ASCO 2012 (32) . At a median follow-up of 12.3 months, median OS and PFS were 12.1 and 7.4 months, respectively. AEs (67% grade 3 and 20% grade 4), especially during the chemo-RT portion, were considerable and affected administration of subsequent systemic maintenance therapy. The observed toxicities in the current dose finding study suggest that the panitumumab dose was too high, at least during CRT. Other anti-EGFR mAbs like cetuximab have also been evaluated as a treatment strategy for LAPC. Panitumumab and cetuximab both target the EGFR but they differ in their isotype and they might differ in their mechanism of action. An OS of 7.5 months was reported for radiotherapy in combination with single agent cetuximab. This OS is less than for most CRT trials in LAPC but the toxicity was also very moderate(33). Crane et al. demonstrated a favorable OS of 19.2 months of cetuximab in combination with induction chemotherapy (gemcitabine and oxaliplatin) in LAPC followed by capecitabine based CRT (50.4Gy) in combination with cetuximab(34). The toxicity was comparable to the current study, except an increased incidence of sensory neuropathy, which is associated with oxaliplatin.
Other targeted therapies like the VEGF mAb bevacizumab, the tyrosine kinase inhibitor sorafenib and the cyclooxygenase-2 inhibitor, celecoxib, have also been investigated in combination with chemoradiation, but did not result in a significant 
improvement in OS (28, 35, 36) . The combination of erlotinib, bevacizumab, and external beam radiation therapy without chemotherapy in a phase 1 trial was reasonably well-tolerated as presented at ASCO GI in 2011 (37) . CRT trials that have been performed studying the added effect of targeted therapy are summarized in Table 4 .
Novel local therapies such as radiofrequency ablation (RFA) and irreversible electroporation (IRE) are used and studied in increasing frequency in the treatment of LAPC (38) . RFA is a thermal local therapy based on high-frequency electrical currents. Variable outcomes of the efficacy of RFA are described in small nonrandomized trials (39, 40) . IRE is a promising non-thermal ablative technique using direct current, which irreversibly damages the cell's homeostatic mechanism, causing apoptosis. Two series were reported of IRE in PDAC with promising results and manageable toxicity (41, 42) . Stereotactic body radiotherapy (SBRT) is a recent advancement that allows for the precise delivery of a large ablative radiation dose to the tumor in one to five fractions. A total dose between 24-36 Gy in 1-5 fractions has been reported (43) (44) (45) . SBRT could be delivered quickly and effectively in patients with LAPC with acceptable side effects and minimal interference with gemcitabine chemotherapy. An advantage of IRE and stereotactic radiotherapy over RFA is that they can be used for tumors in close proximity to large vessels without risk of In conclusion, we report that the use of panitumumab at a MTD of 1.5mg/kg, can be safely added to gemcitabine-based chemoradiotherapy in patients with LAPC. The observed PFS and OS rates suggest some efficacy. These observations support the further evaluation of this combination in a phase II study along with the search of predictive biomarkers to allow future selection of patients with an increased chance of experiencing clinical benefit from this type of combination therapy. 
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